Kusajili – Clinical trials directory

Result of your search per sponsor: Johnson & Johnson Pharamceutical Resarch & Development, L.L.C

Woman and Man Max 99 years
Johnson & Johnson Pharamceutical Resarch & Development, L.L.C Update Il y a 4 ans

A One-Year, Randomized, Open-Label, Parallel-Arm, Phase III Long-Term Safety Trial, with Controlled Adjustment of Dose, of Multiple Doses of CG5503 PR* and Oxycodone CR in Subjects with Chronic Pain The primary objective of the trial is the evaluation of the safety profile of CG5503 PR base at doses ranging between 100 mg and 250 mg BID over long term exposure of up to one year.

Country None
organs None
Specialty None

Closed trial

More information